A three-peptide cancer vaccine given after surgery improved 5-year esophageal cancer-specific survival from 32.4% to 60.0% in patients with lymph node-positive disease.
60.0% vs 32.4% five-year survivalCancer-specific survival in esophageal cancer patients receiving the peptide vaccine versus controls, with even greater benefit in tumors lacking PD-L1
What the researchers found
The vaccine group achieved a 5-year esophageal cancer-specific survival (ECSS) of 60.0% compared to 32.4% in the control group (P = 0.045). While relapse-free survival did not reach statistical significance (5-year RFS: 45.3% vs 32.5%), the recurrence rate significantly decreased with the number of peptide antigens that successfully induced antigen-specific cytotoxic T lymphocytes, suggesting a dose-response relationship in immune activation.
The survival benefit was most pronounced in patients whose tumors were CD8+ and PD-L1 double negative: vaccinated patients in this subgroup achieved 68.0% 5-year ECSS versus only 17.7% in controls (P = 0.010). This suggests the tumor immune microenvironment strongly influences peptide vaccine effectiveness.
Why it matters
Esophageal squamous cell cancer with lymph node involvement has one of the worst prognoses in oncology, and there are limited adjuvant treatment options after surgery. This peptide vaccine nearly doubled 5-year cancer-specific survival in a patient population where the expected survival rate is around 30%. The identification of tumor immune microenvironment markers that predict response could enable patient selection, moving toward precision immunotherapy.
How the study worked
This was a non-randomized prospective phase II clinical trial (UMIN000003557). Esophageal squamous cell carcinoma patients with pathologically positive lymph nodes after curative resection following preoperative therapy were allocated to vaccine or control groups based on their HLA-A status (HLA-A*24 positive patients received the vaccine). The vaccine consisted of 1 mg each of three tumor-specific epitope peptides (upregulated lung cancer 10, CDCA1, and KIAA0101), injected subcutaneously 10 times weekly then 10 times biweekly. Primary endpoint was relapse-free survival; secondary endpoint was ECSS.
What this study cannot tell us
This was a non-randomized trial with allocation based on HLA-A status, introducing potential selection bias between groups. The sample size of 63 patients is small for drawing definitive survival conclusions. The primary endpoint (relapse-free survival) did not reach statistical significance; only the secondary endpoint (cancer-specific survival) was significant. Subgroup analyses in small trials carry a high risk of false-positive findings. Phase III randomized confirmation is essential before clinical adoption.
How to read the evidence
This is a phase II non-randomized clinical trial, providing moderate-quality evidence. The significant survival improvement is encouraging, but the non-randomized design, small sample size, and positive result only on the secondary endpoint mean these findings must be confirmed in a phase III randomized controlled trial before changing clinical practice.
When this study was published
Published in 2022 with data from the UMIN000003557 trial, this study reflects relatively recent clinical evidence. The trial's results should prompt phase III investigation, though the current status of follow-up studies is not specified in this publication.
The bigger picture
Peptide cancer vaccines have historically shown modest results in clinical trials, making this study's survival improvement particularly notable. The finding that the tumor immune microenvironment (specifically CD8+ and PD-L1 status) predicts vaccine response aligns with the broader immunotherapy field's move toward biomarker-guided treatment selection. Combining peptide vaccines with checkpoint inhibitors in PD-L1-positive tumors is an obvious next step that could extend benefit to a wider patient population.
Questions still open
- Would combining this peptide vaccine with anti-PD-1/PD-L1 checkpoint inhibitors extend the survival benefit to patients with PD-L1-positive tumors?
- Can the number of peptides inducing T cell responses serve as an on-treatment biomarker to identify responding patients early?
- Will the survival benefit hold up in a larger, randomized phase III trial with HLA-matched controls?
Common questions
How does a peptide cancer vaccine work differently from chemotherapy?
Why did the vaccine work better in patients with CD8+/PD-L1 double negative tumors?
Read the original research
Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects.
Annals of surgery, 275(1), e155-e162
Citation
Yasuda, Takushi; Nishiki, Kohei; Hiraki, Yoko; Kato, Hiroaki; Iwama, Mitsuru; Shiraishi, Osamu; Yasuda, Atsushi; Shinkai, Masayuki; Kimura, Yutaka; Sukegawa, Yasushi; Chiba, Yasutaka; Imano, Motohiro; Takeda, Kazuyoshi; Satou, Takao; Shiozaki, Hitoshi; Nakamura, Yusuke. (2022). Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects.. Annals of surgery, 275(1), e155-e162. https://doi.org/10.1097/SLA.0000000000003880